ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2–expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177 Lu somatostatin analogue (SSA) therapy: Initial safety analysis.
| Autor: | Morris, Michael, Ulaner, Gary A., Halperin, Daniel M., Strosberg, Jonathan R., Mehr, Samuel H., Li, Daneng, Soares, Heloisa P., Anthony, Lowell Brian, Kotiah, Sandy Diana, Jacene, Heather, Pavel, Marianne E., Kunz, Pamela L., Ferreira, Denis Vasconcelos, Li, Joanne, Ma, Kimberly, Rearden, Jessica, Moran, Susan, Hope, Thomas A., Singh, Simron |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p4132-4132, 1p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|